REGENXBIO Inc.
RGNX Real Time Price USDRecent trades of RGNX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by RGNX's directors and management
Government lobbying spending instances
-
$15,000 Apr 23, 2024 Issue: None
-
$91,000 Jan 22, 2024 Issue: Taxation/Internal Revenue Code Immigration Copyright/Patent/Trademark Trade (domestic/foreign) Health Issues
-
$94,000 Oct 16, 2023 Issue: Taxation/Internal Revenue Code Immigration Copyright/Patent/Trademark Trade (domestic/foreign) Health Issues
-
$90,000 Jul 19, 2023 Issue: Taxation/Internal Revenue Code Immigration Copyright/Patent/Trademark Trade (domestic/foreign) Health Issues
-
$70,000 Jan 18, 2023 Issue: Taxation/Internal Revenue Code Immigration Copyright/Patent/Trademark Trade (domestic/foreign) Health Issues
-
$70,000 Oct 15, 2022 Issue: Taxation/Internal Revenue Code Immigration Copyright/Patent/Trademark Trade (domestic/foreign) Health Issues
-
$82,000 Jul 20, 2022 Issue: Taxation/Internal Revenue Code Immigration Copyright/Patent/Trademark Trade (domestic/foreign) Health Issues
-
$150,000 Apr 20, 2022 Issue: Taxation/Internal Revenue Code Immigration Copyright/Patent/Trademark Trade (domestic/foreign) Health Issues
-
$60,000 Jan 17, 2022 Issue: None
-
$75,000 Dec 14, 2021 Issue: None
-
$40,000 Jul 20, 2021 Issue: None
-
$60,000 Apr 21, 2021 Issue: None
-
$60,000 Jan 21, 2021 Issue: None
-
$60,000 Oct 20, 2020 Issue: None
-
$185,000 Jul 20, 2020 Issue: None
-
$110,000 Apr 20, 2020 Issue: None
-
$50,000 Jan 31, 2020 Issue: None
-
$50,000 Oct 21, 2019 Issue: Immigration Health Issues Copyright/Patent/Trademark Trade (domestic/foreign)
-
$130,000 Aug 06, 2019 Issue: Health Issues Trade (domestic/foreign) Copyright/Patent/Trademark
-
$50,000 Apr 19, 2019 Issue: Health Issues Copyright/Patent/Trademark Trade (domestic/foreign)
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Anion exchange chromatography for recombinant aav production Aug. 27, 2024
-
Patent Title: Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) May. 21, 2024
-
Patent Title: Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) produced by human neural or glial cells Mar. 28, 2023
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of RGNX in WallStreetBets Daily Discussion
Recent insights relating to RGNX
Recent picks made for RGNX stock on CNBC
ETFs with the largest estimated holdings in RGNX
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view RGNX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.